WO2014029953A1 - Composition pharmaceutique de cinacalcet extrudée à l'état fondu - Google Patents

Composition pharmaceutique de cinacalcet extrudée à l'état fondu Download PDF

Info

Publication number
WO2014029953A1
WO2014029953A1 PCT/GB2013/000347 GB2013000347W WO2014029953A1 WO 2014029953 A1 WO2014029953 A1 WO 2014029953A1 GB 2013000347 W GB2013000347 W GB 2013000347W WO 2014029953 A1 WO2014029953 A1 WO 2014029953A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
cinacalcet
cellulose
tablets
Prior art date
Application number
PCT/GB2013/000347
Other languages
English (en)
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Original Assignee
Cipla Limited
Turner, Craig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, Turner, Craig filed Critical Cipla Limited
Publication of WO2014029953A1 publication Critical patent/WO2014029953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a hot-melt extruded pharmaceutical composition comprising a calcimimetic drug.
  • the invention also relates to processes for the preparation of the said pharmaceutical composition and its use for the treatment and/or prevention of hyperparathyroidism.
  • lipophilic drugs have higher affinity to their respective target receptors and therefore the solubility increases which in turn results in the increment of its bioavailability.
  • the drawback to this fundamental is that lipophilic drugs tend to have a higher molecular weight thus affecting their absorption and amounting to decreased solubility. So either the drug is more soluble and less lipophilic which in turn makes it less bioavailable or a drug can be more lipophilic and less soluble which also makes it less bioavailable which ultimately proves that there are very few cases where bioavailability can be increased. This principle applies to over 40% of present potential actives.
  • Cinacalcet belongs to the class of naphthalenes and phenylpropylamines and is a calcimimetic drug used in the treatment of hyperparathyroidism in chronic kidney disease especially for those who require dialysis. It functions by reducing the calcium levels caused by increasing the sensitivity of calcium receptors to extracellular calcium. Cinacalcet is chemically known as [(lR)-l-(naphthalen-l-yl)ethyl]( ⁇ 3-[3-(trifluoromethyl)phenyl]propyl ⁇ )amine and its chemical structure is as follows:-
  • Cinacalcet is a type II calcimimetic (i.e. it mimics the action of calcium on tissues). It binds to the transmembrane region of the calcium-sensing receptor, which leads to a different structural configuration that is more sensitive to serum calcium. Unlike vitamin D sterols, cinacalcet does not increase serum calcium levels; therefore, adverse effects associated with hypercalcemia can be avoided.
  • Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) is a progressive disease, associated with increase in parathyroid hormone (PTH) levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis.
  • the calcium-sensing receptors on the surface of the chief cell of the parathyroid gland are the principal regulators of parathyroid hormone secretion (PTH). Cinacalcet directly lowers parathyroid hormone levels by increasing the sensitivity of the calcium sensing receptors to activation by extracellular calcium, resulting in the inhibition of PTH secretion. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
  • Cinacalcet is well absorbed orally but the absorption and bioavailability depends on the food intake of the patient and it gets affected by fed-fast conditions. Cinacalcet has been proved to be better absorbed when administered with food or just after a meal as compared to fasting conditions.
  • Cinacalcet is commercially available as Sensipar ® in the United States of America and Mimpara ® in Europe for secondary hyperparathyroidism in chronic kidney disease, hypercalcemia in parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism and cannot undergo parathyroidectomy.
  • the recommended daily dose of cinacalcet is 30 mg and goes up to 120 mg daily depending on the severity of the condition.
  • WO 2011047837 discloses an intermediate formed by melt processing crystalline cinacalcet or any one of its pharmaceutically accepted salts with a matrix former or any other excipients.
  • it is a very well known phenomenon that amorphous form of drug is always more suited than the crystalline counterpart of the drug due to an increased amount of energy associated, increased surface area as well as enhanced bioavailability.
  • WO 2008027522 discloses immediate and controlled release solid composites of cinacalcet. Further this application also claims a method for preparing a solid composite of cinacalcet by hot melt extrusion. However, this application neither discloses details about the process of hot melt extrusion nor exemplifies it.
  • WO 2005034928 discloses an immediate release pharmaceutical composition
  • cinacalcet having a controlled dissolution profile.
  • the tablets contain cinacalcet in a micronized form with an active ingredient content of about 18%.
  • the tablets need to be administered with meals or shortly after meals, because the bioavailability is increased by 50% to 80% with concomitant food intake.
  • micronization of cinacalcet is accompanied, by some disadvantages such as undesirable low fluidity.
  • the micronized active ingredient may lead to non-uniform drug distribution within the pharmaceutical formulation to be pressed. Further, due to increase of the surface area during micronization, oxidation of the drug may occur.
  • WO 2007124465 discloses a stable anti-irritant emulsion formulation of cinacalcet in the form of an injectable.
  • WO 2008064202 discloses modified release formulations containing cinacalcet and their methods of preparation. Modified or sustained release dosage forms are commonly used for special purposes; however, immediate-release dosage forms are always desirable or preferred.
  • WO 2010034497 discloses cinacalcet formulations in the form of tablets with bimodal pore size and pH adjusters so as to increase its solubility and stability.
  • WO 2011146583 discloses a cinacalcet formulation with increased solubility wherein cinacalcet is nanosized below 200 nm.
  • WO 2012071535 discloses hard shell capsules containing a granular powder formulation of Cinacalcet which can be sprinkled on and mixed with food or drinks and then administered orally to the pediatric patients
  • the object of the present invention is to provide a pharmaceutical composition of cinacalcet having improved solubility.
  • Another object of the present invention is to provide a cinacalcet formulation which has higher bioavailability.
  • Yet another object of the present invention is to provide a cinacalcet formulation which can be preferably administered without food.
  • One more object of the present invention is to provide a pharmaceutical composition of cinacalcet having improved stability.
  • Another object of the present invention is to provide a process for preparing the pharmaceutical composition comprising cinacalcet.
  • Another object of the present invention is to provide a method for treatment and/or prevention of secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism by administering a pharmaceutical composition comprising cinacalcet.
  • Another object of the present invention is to provide a use of the pharmaceutical composition comprising cinacalcet in the manufacture of a medicament for treating secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism.
  • a pharmaceutical composition comprising cinacalcet and at least one pharmaceutically acceptable polymer.
  • the pharmaceutical composition is a hot melt extruded pharmaceutical composition.
  • the composition comprises one or more suitable pharmaceutically acceptable excipients.
  • compositions of the present invention include providing cinacalcet formulations with higher solubility, stability and/or bioavailablity.
  • Pharmaceutical compositions of the present invention may also be administered to patients without food.
  • a process for preparing a pharmaceutical composition of the present invention comprising hot melt extrusion of the cinacalcet polymer blend to form extrudates and optionally mixing it with one or more pharmaceutically acceptable excipients.
  • a method for the treatment of secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism comprising administering a pharmaceutical composition of the present invention to a subject in need thereof.
  • a pharmaceutical composition of the present invention in the manufacture of a medicament for treating secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism.
  • composition of the present invention for use in the treatment of secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism.
  • Cinacalcet is very soluble in its amorphous form when taken orally but the main drawback is that it tends to convert to its stable crystalline form. Absorption of Cinacalcet also depends on the fasting condition of the patient. If the patient is well fed and the dose is administered with the meal or right after the meal, the absorption is optimal but the contrary results in minimal absorption. Therefore, the time lapse between the drug administration and food intake plays a major role in the absorption and bioavailability patterns of cinacalcet.
  • the inventors of the present invention have found that the solubility, bioavailability as well as stability of cinacalcet was greatly improved when cinacalcet was formulated using hot melt technology.
  • Hot melt extrusion enables the drug to have exceptional absorption and solubility and minimizes its dependence on the food intake of the patient.
  • the inventors made sure that the extruded form of cinacalcet can be taken by the patients at any time of the day without having an effect on its bioavailability.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising cinacalcet with a polymeric carrier and optionally one or more pharmaceutically acceptable excipients by hot melt technology.
  • Cromcet is used in broad sense to include not only “Cinacalcet free base” per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable complexes etc.
  • salt refers to salts derived from inorganic or organic acids.
  • Suitable salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, carbonates, bicarbonates, hydrobromide, hydroiodide, 2-hydr xy-ethanesulfonate, lactate, maleate, mandelate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate
  • extrudates refers to solid product solutions, solid dispersions and glass solutions of Cinacalcet with one or more polymers and optionally pharmaceutically acceptable excipients.
  • Cinacalcet can be present in crystalline or amorphous form or a combination thereof.
  • the pharmaceutical compositions of the present invention provide cinacalcet in an amorphous form.
  • the melt-extrusion process comprises the steps of preparing a homogeneous melt of one or more drugs, the polymer and the excipients, and cooling the melt until it solidifies.
  • Melting usually involves heating above the softening point of the polymer.
  • the preparation of the melt can take place in a variety of ways.
  • the mixing of the components can take place before, during or after the formation of the melt.
  • the melt temperature is in the range of about 50° C to about 200° C.
  • Suitable extruders include single screw extruders, intermeshing screw extruders or else multiscrew extruders, preferably twin screw extruders, which can be co-rotating or counter- rotating and, optionally, be equipped with kneading disks.
  • the extrudates can be in the form of beads, granulates, tubes, strands or cylinders and these can be further processed into any desired shape.
  • the cinacalcet compositions of the invention generally comprise at least one pharmaceutically acceptable water soluble and/or insoluble polymer or combination thereof and optionally one or more pharmaceutically acceptable excipients.
  • the cinacalcet compositions of the present invention can be administered to a subject via any conventional means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray.
  • parenterally e.g., intravenous, intramuscular, or subcutaneous
  • intracisternally e.g., intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray.
  • extrudates/granules of cinacalcet of the present invention may be formulated into any suitable dosage form, including but not limited to liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, lyophilized formulations, tablets, capsules, immediate release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.
  • the cinacalcet compositions may be formulated for parenteral injections (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol forms, foams (vaginal, rectal), vaginal, rectal, ocular, local (powders, ointments or drops), buccal, intracistemal, intraperitoneal, or topical administration, and the like.
  • parenteral injections e.g., intravenous, intramuscular, or subcutaneous
  • buccal intracistemal, intraperitoneal, or topical administration, and the like.
  • Solid dosage forms are preferably in the form of tablets, coated tablets, powders, powders for reconstitution, pellets, beads, mini-tablets, film coated tablets, bilayered tablets, tablet in tablet, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates, capsules (filled with powders, powders for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, orally disintegrating MUPS, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates), sachets (filled with powders, pellets, beads, mini- tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, modified release tablets or capsules, effervescent granules, granules, and microspheres, multiparticulates) and sprinkles and the like,
  • Liquid dosage forms according to the present invention for oral administration include pharmaceutically acceptable emulsions, liquid dispersions, sprays, solutions, suspensions, syrups, dry syrup and elixirs.
  • Water soluble polymers or hydrophilic polymer which may be used in the pharmaceutical composition of the present invention, include, but are not limited to, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer (Soluplus), homopolymers and co-polymers of N-vinyl lactams, especially homopolymers and co-polymers of N- vinyl pyrrolidone e.g.
  • polyvinylpyrrolidone PVP
  • co-polymers of PVP and vinyl acetate co-polymers of N-vinyl pyrrolidone and vinyl acetate (Copovidone) or vinyl propionate
  • dextrins such as grades of maltodextnn
  • cellulose esters and cellulose ethers high molecular polyalkylene oxides such as polyethylene oxide and polypropylene oxide and co-polymers of ethylene oxide, propylene oxide, hydroxypropyl methylcellulose (HPMC, also known as hypromellose), hydroxypropylcellulose (HPC), methylcellulose, carmellose (carboxymethylcellulose), hydroxyethylcellulose (HEC), hydroxymethylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, carboxymethylcellulose calcium, xanthan gum, sodium alginate, ammonium alginate, polyethylene oxide, potassium alginate, calcium alginate, propylene glycol alginate, alginic acid
  • Water insoluble polymers or hydrophobic which may be used in the pharmaceutical composition of the present invention, include, but are not limited to, acrylic copolymers, ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, poly (alkyl) methacrylate, and copolymers of acrylic or methacrylic acid esters, ammonio methyacrylate copolymer, methyacrylic acid copolymers, methacrylic acid-acrylic acid ethyl ester copolymer, methacrylic acid esters neutral copolymer, polyvinyl acetate, waxes, such as, beeswax, carnauba wax, microcrystalline wax, candelilla wax, spermaceti, montan wax, hydrogenated vegetable oil, lecithin, hydrogenated cottonseed oil, hydrogenated tallow, paraffin wax, shellac wax
  • fatty acids such as, stearic acid, palmitic acid, lauric acid, eleostearic acids, and the like
  • fatty alcohols such as, lauryl alcohol, cetostearyl alcohol, stearyl alcohol, cetyl alcohol and myristyl alcohol
  • fatty acid esters such as, glyceryl monostearate, glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate and glyceryl behenate
  • vegetable oil such as, hydrogenated castor oil; mineral oil and the like or mixtures thereof.
  • Water-swellable polymers for use in the pharmaceutical composition of the present invention may comprise one or more, polyethylene oxide having a molecular weight of 100,000 to 8,000,000; poly (hydroxy alkyl methacrylate) having a molecular weight of from 30,000 to 5,000,000; poly (vinyl) alcohol, having a low acetal residue, which is cross-linked with glyoxal, formaldehyde or glutaraldehyde and having a degree of polymerization of from 200 to 30,000; a mixture of methyl cellulose, cross- linked agar and carboxymethyl cellulose; a water-insoluble, water-swellable copolymer produced by forming a dispersion of a finely divided copolymer of maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene cross-linked with from 0.001 to 0.5 moles of saturated cross-linking agent per mole of maleic anhydride in the copolymer; Carbopol ® carb
  • Other pharmaceutically acceptable excipients may include, but are not limited to, plasticizers, disintegrating agents, lubricants, glidants, diluents, binders, chelating agents, coating agents and the like or mixtures thereof.
  • Plasticizers reduce the viscosity of the polymer melt and thereby allow for lower processing temperature and extruder torque during hot melt extrusion. They further decrease the glass transition temperature of the polymer.
  • Plasticizers which may be used in the pharmaceutical composition of the present invention, include, but are not limited to propylene glycol, polysorbates such as sorbitan monolaurate (Span 20), sorbitan monopalmitate, sorbitan monostearate, sorbitan monoisostearate; citrate ester type plasticizers like triethyl citrate, citrate phthalate; propylene glycol; glycerin; polyethylene glycol (low & high molecular weight); triacetin; dibutyl sebacate, tributyl sebacate; dibutyltartrate, dibutyl phthalate, glycerol palmitosterate and the like or mixtures thereof.
  • the plasticizers may be present in an amount of from about 5 to 20 % of polymer in the composition.
  • Suitable disintegrating agents which may be used in the pharmaceutical composition of the present invention, include, but are not limited to hydroxyl propyl cellulose, dihydroxyypropyl cellulose, sodium carboxy methyl cellulose, carboxy methyl cellulose, calcium carboxy methyl cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, carboxymethyl starch, hydroxylpropyl starch, potato starch, maize starch, alginic acid or a salt, modified starches, calcium silicates, low substituted hydroxy- propylcellulose and the like or mixtures thereof.
  • the disintegrating agents may be present in an amount of from about 0.5 to 20 % w/w.
  • Suitable lubricants, anti-adherents and glidants which may be used in the pharmaceutical composition of the present invention, include, but are not limited to, stearic acid and pharmaceutically acceptable salts or esters thereof (for example, magnesium stearate, calcium stearate, sodium stearyl fumarate or other metallic stearate), talc, waxes (for example, microcrystalline waxes) and glycerides, light mineral oil, PEG, silica acid or a derivative or salt thereof (for example, silicates, silicon dioxide, colloidal silicon dioxide and polymers thereof, crospovidone, magnesium aluminosilicate and/or magnesium alumino metasilicate), sucrose ester of fatty acids, hydrogenated vegetable oils (for example, hydrogenated castor oil), and the like or mixtures thereof.
  • stearic acid and pharmaceutically acceptable salts or esters thereof for example, magnesium stearate, calcium stearate, sodium stearyl fumarate or other metallic stea
  • the lubricants and glidants may be present in an amount of from about 0.05 to 1 % w/w.
  • Suitable diluents or bulking agents which may be used in the pharmaceutical composition of the present invention, include, but are not limited to microcrystalline cellulose, silicified microcrystalline cellulose, lactose, calcium phosphate, starch, dicalcium phosphate,sorbitol/mannitol, sucrose/methyl dextrins, saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, lactose, dextrose, sucrose, fructose, maltose, mannitol, erythritol, sorbitol, xylitol, lactitol, and the like or mixtures thereof.
  • Suitable binders may include, one or more of, but not limited to polyvinyl pyrrolidone (also known as povidone), polyethylene glycol, acacia, alginic acid, agar, calcium carragenan, cellulose derivative such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, gelatin, gum arabic, guar gum, tragacanth, sodium alginate, copovidone, starches, and the like or any other pharmaceutically acceptable substances with cohesive properties, or any combination thereof.
  • polyvinyl pyrrolidone also known as povidone
  • polyethylene glycol also known as povidone
  • acacia alginic acid
  • agar calcium carragenan
  • cellulose derivative such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or sodium carb
  • Suitable chelating agents include, one or more of, but not limited to ethylenediaminetetraacetic acid (EDTA), disodium EDTA and derivatives thereof, citric acid and derivatives thereof, niacinamide and derivatives thereof, and sodium desoxycholate and the like or mixtures thereof.
  • EDTA ethylenediaminetetraacetic acid
  • disodium EDTA and derivatives thereof citric acid and derivatives thereof
  • niacinamide and derivatives thereof sodium desoxycholate and the like or mixtures thereof.
  • the pharmaceutical composition may also optionally be coated, i.e. seal coated and/or enteric coated and/or film coated.
  • the pharmaceutical composition may be seal coated and finally film coated or it may be seal coated and further enteric coated.
  • compositions of the invention may be film coated.
  • the film coating polymer may be present in an amount from about 2 to 10 % w/w.
  • seal coat between the core containing cinacalcet, and an enteric coat.
  • the seal coat can comprise one or more pharmaceutically acceptable film-forming polymers and pharmaceutically acceptable excipients(s).
  • the seal coat provides a smooth base for the application of the enteric coat, prolongs the resistance of the core to the acidic conditions, improves stability by minimizing the interaction between drug in the core and the enteric polymer in the enteric layer from coming into direct contact with each other; and also improves stability of drug from light exposure.
  • the smoothing function of the separating coat is purely mechanical, the objective of which is to improve the coverage of the enteric coat and to avoid thin spots in it, caused by bumps and irregularities on the core.
  • the seal coat can comprise film forming polymeric materials, such as but not limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, methylcellulose, carboxymethylcellulose, hypromellose, acacia, gelatin to increase adherence and coherence of the seal coat.
  • the seal coating polymer/plasticizer may be present in an amount of from about 0.05 to 1 % w/w.
  • an enteric coat is present over the seal coat.
  • the enteric coat comprises of materials such as, but not limited to, neutralized methacrylic acid copolymer such as, EUDRAGIT L 30 D- 55, EUDRAGIT L 100-55, EUDRAGIT S 100, EASTACRYL 30D, KOLLICOAT MAE 30 DP, KOLLICOAT MAE 100 P; cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate and combinations thereof.
  • the pharmaceutical composition according to the present invention may further comprise at least one additional active ingredient.
  • the additional active ingredient may be another calcium receptor-active compound, or it may be an active ingredient having a different therapeutic activity.
  • additional active ingredients include, for example, vitamins and their analogs, such as vitamin D and analogs thereof, antibiotics, and cardiovascular agents.
  • the process for preparing the pharmaceutical composition of the invention can comprise forming a powder blend, which melts on passage through a heated barrel of an extruder, to form a molten solution product and is then subsequently cooled to form an extrudate.
  • the extrudate is cut into pieces after solidification and can be further processed into suitable dosage forms.
  • the present invention may further be allowed to form granules which may be compressed to form tablets, powders, powders for reconstitution, pellets, beads, mini- tablets, film coated tablets, bilayered tablets, tablet in tablet, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates, capsules (filled with powders, powders for reconstitution, pellets, beads, mini- tablets, pills, micro-pellets, small tablet units, MUPS, orally disintegrating MUPS, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates), sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, modified release tablets or capsules, effervescent granules, granules, and microspheres, multiparticulates) and sprinkles and the like.
  • This process involves heating the polymer(s) to soften it, without melting it, and mixing the active ingredient(s) with the polymer(s) to form granules.
  • the process can be carried out in the same type of extrusion apparatus as the hot melt extrusion process, except that the product is not extruded through the extrusion nozzle of the apparatus.
  • the present invention also provides a method of treating secondary hyperparathyroidism, hypercalcemia in patients with parathyroid carcinoma, severe hypercalcemia in patients with primary hyperparathyroidism which method comprises administration of a therapeutically effective amount of a pharmaceutical composition of the present invention.
  • step (2) Cinacalcet, Polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer (Soluplus ® ) and propylene glycol were mixed with the blend obtained in step (1) 3) The mixture obtained in step (2) was subjected to hot melt extrusion.
  • step (3) The extrudates obtained in step (3) were further milled and sized which was followed by addition of microcrystalline cellulose, crospovidone and further lubricated with magnesium stearate.
  • step (4) The lubricated mixture obtained in step (4) was compressed to form a tablet which was seal
  • step (2) Cinacalcet, Polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer (Soluplus ® ) and propylene glycol were mixed with the blend obtained in step (1) 3) The mixture obtained in step (2) was subjected to hot melt extrusion.
  • step (3) The extrudates obtained in step (3) were further milled and sized which was followed by addition of microcrystalline cellulose, crospovidone and further lubricated with magnesium stearate.
  • Lubricated granules/extrudates which were obtained in step (4) were filled in capsules made of Gelatin /Hydroxy propyl methyl cellulose, Carrageenan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique qui comporte du cinacalcet ou un sel, un solvate, un dérivé, un hydrate, un anhydride, un énantiomère, un polymorphe, un promédicament ou un complexe de celui-ci, ainsi qu'au moins un polymère de qualité pharmaceutique. Un procédé de préparation d'une composition pharmaceutique comportant du cinacalcet ou un sel, un solvate, un dérivé, un hydrate, un anhydride, un énantiomère, un polymorphe, un promédicament ou un complexe de celui-ci, ainsi qu'au moins un polymère pharmaceutiquement acceptable, comporte l'extrusion à l'état fondu du mélange de polymère de cinacalcet de manière à former des extrudats et son mélange facultatif avec un ou plusieurs excipients qui sont pharmaceutiquement acceptables.
PCT/GB2013/000347 2012-08-21 2013-08-16 Composition pharmaceutique de cinacalcet extrudée à l'état fondu WO2014029953A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2429MU2012 2012-08-21
IN2429/MUM/2012 2012-08-21

Publications (1)

Publication Number Publication Date
WO2014029953A1 true WO2014029953A1 (fr) 2014-02-27

Family

ID=49115539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/000347 WO2014029953A1 (fr) 2012-08-21 2013-08-16 Composition pharmaceutique de cinacalcet extrudée à l'état fondu

Country Status (1)

Country Link
WO (1) WO2014029953A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105596299A (zh) * 2016-01-08 2016-05-25 中国药科大学 一种泡腾性速释微丸及其制备方法
RU2587331C1 (ru) * 2015-06-19 2016-06-20 Общество с ограниченной ответственностью "Полигепазол" Способ получения фармацевтической композиции адеметионина и его лекарственной формы
WO2017050438A1 (fr) * 2014-08-07 2017-03-30 Opko Ireland Global Holdings Ltd. Traitement d'appoint avec la 25-hydroxyvitamine d et articles associés
CN106890166A (zh) * 2015-12-17 2017-06-27 北京泰德制药股份有限公司 含有钙受体活性化合物的皮肤外用制剂
CN107095899A (zh) * 2017-06-27 2017-08-29 西安远大德天药业股份有限公司 一种藏茵陈药物组合物的制备方法及应用
US10300078B2 (en) 2013-03-15 2019-05-28 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
WO2019186516A1 (fr) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci
CN110548008A (zh) * 2018-06-01 2019-12-10 广东东阳光药业有限公司 阿考替胺固体分散体及其组合物
US10668089B2 (en) 2006-06-21 2020-06-02 Opko Ireland Global Holdings, Ltd. Method of treating and preventing secondary hyperparathyroidism
US11007204B2 (en) 2006-02-03 2021-05-18 Opko Renal, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US11154509B2 (en) 2007-04-25 2021-10-26 Eirgen Pharma Ltd. Methods for controlled release oral dosage of a vitamin D compound
US11173168B2 (en) 2016-03-28 2021-11-16 Eirgen Pharma Ltd. Methods of treating vitamin D insufficiency in chronic kidney disease
GB2608701A (en) * 2021-06-03 2023-01-11 Norbrook Lab Ltd Sol-gel compositions for veterinary use
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027522A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Composites solides d'un composé actif vis-à-vis du récepteur calcique
WO2008064202A2 (fr) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
EP2314286A1 (fr) * 2009-10-21 2011-04-27 Ratiopharm GmbH Cinacalcet en granulés à fondre

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027522A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Composites solides d'un composé actif vis-à-vis du récepteur calcique
WO2008064202A2 (fr) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
EP2314286A1 (fr) * 2009-10-21 2011-04-27 Ratiopharm GmbH Cinacalcet en granulés à fondre

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911398B2 (en) 2006-02-03 2024-02-27 Opko Renal, Llc Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US11007204B2 (en) 2006-02-03 2021-05-18 Opko Renal, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US10668089B2 (en) 2006-06-21 2020-06-02 Opko Ireland Global Holdings, Ltd. Method of treating and preventing secondary hyperparathyroidism
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
US11154509B2 (en) 2007-04-25 2021-10-26 Eirgen Pharma Ltd. Methods for controlled release oral dosage of a vitamin D compound
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US10357502B2 (en) 2013-03-15 2019-07-23 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US11253528B2 (en) 2013-03-15 2022-02-22 Eirgen Pharma Ltd. Stabilized modified release Vitamin D formulation and method of administering same
US10300078B2 (en) 2013-03-15 2019-05-28 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US10350224B2 (en) 2013-03-15 2019-07-16 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
AU2016325209B2 (en) * 2014-08-07 2022-04-14 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10493084B2 (en) 2014-08-07 2019-12-03 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
WO2017050438A1 (fr) * 2014-08-07 2017-03-30 Opko Ireland Global Holdings Ltd. Traitement d'appoint avec la 25-hydroxyvitamine d et articles associés
US11007205B2 (en) 2014-08-07 2021-05-18 Eirgen Pharma Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN108135868A (zh) * 2014-08-07 2018-06-08 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d及其制品的辅助疗法
IL258259A (en) * 2014-08-07 2018-05-31 Opko Ireland Global Holdings Ltd Complementary treatment with the help of hydroxyvitamin d and preparations that include it
US11738033B2 (en) 2014-08-07 2023-08-29 Eirgen Pharma Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
RU2587331C1 (ru) * 2015-06-19 2016-06-20 Общество с ограниченной ответственностью "Полигепазол" Способ получения фармацевтической композиции адеметионина и его лекарственной формы
CN106890166A (zh) * 2015-12-17 2017-06-27 北京泰德制药股份有限公司 含有钙受体活性化合物的皮肤外用制剂
CN105596299A (zh) * 2016-01-08 2016-05-25 中国药科大学 一种泡腾性速释微丸及其制备方法
US11173168B2 (en) 2016-03-28 2021-11-16 Eirgen Pharma Ltd. Methods of treating vitamin D insufficiency in chronic kidney disease
CN107095899A (zh) * 2017-06-27 2017-08-29 西安远大德天药业股份有限公司 一种藏茵陈药物组合物的制备方法及应用
CN107095899B (zh) * 2017-06-27 2020-06-09 西安远大德天药业股份有限公司 一种藏茵陈药物组合物的制备方法及应用
WO2019186516A1 (fr) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci
CN110548008A (zh) * 2018-06-01 2019-12-10 广东东阳光药业有限公司 阿考替胺固体分散体及其组合物
CN110548008B (zh) * 2018-06-01 2024-04-26 广东东阳光药业股份有限公司 阿考替胺固体分散体及其组合物
GB2608701A (en) * 2021-06-03 2023-01-11 Norbrook Lab Ltd Sol-gel compositions for veterinary use
GB2608701B (en) * 2021-06-03 2024-02-21 Norbrook Lab Ltd Sol-gel compositions for veterinary use

Similar Documents

Publication Publication Date Title
WO2014029953A1 (fr) Composition pharmaceutique de cinacalcet extrudée à l'état fondu
US8715728B2 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
KR101156916B1 (ko) 이마티닙 및 방출 지연제를 포함하는 제약 조성물
US20110027359A1 (en) Novel Pharmaceutical Compositions Comprising Levetiracetam
EP1830855A1 (fr) Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee
EP2481411A1 (fr) Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
CN106232144B (zh) 固体分散体
CA2911486C (fr) Formulation a liberation modifiee
WO2019073477A1 (fr) Composition pharmaceutique d'aprémilast à libération prolongée
JP2010540547A (ja) アリスキレンおよびバルサルタンのガレヌス製剤
JP2010519200A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
JP5881700B2 (ja) ブロナンセリン経口放出制御型医薬組成物
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
WO2006094640A2 (fr) Association de roflumilast et d'un inhibiteur de l'integrine, et procede de traitement
KR20120014583A (ko) 타르타르산 염 형태의 데스페소테로딘
WO2020115774A1 (fr) Formulations à libération prolongée à charge médicamenteuse élevée
JP5321454B2 (ja) 医薬錠剤の製造法
EP2705839A1 (fr) Composition pharmaceutique contenant de la lacidipine et procédé de préparation
WO2019239432A1 (fr) Complexe de valsartan et de sacubitril trisodique et composition pharmaceutique extrudée à chaud comprenant celui-ci
WO2011147025A1 (fr) Forme pharmaceutique à libération prolongée comprenant de la quétiapine
WO2017163268A2 (fr) Forme d'administration pharmaceutique du divalproex à libération prolongée
US20120064161A1 (en) Modified release niacin pharmaceutical formulations
EP2363120A1 (fr) Mélange contenant du diméboline et de la mémantine
WO2010134938A1 (fr) Formulations pharmaceutiques à base de niacine à libération modifiée
OA16241A (en) Pharmaceutical compositions comprising hydromorphone and naloxone.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13756918

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13756918

Country of ref document: EP

Kind code of ref document: A1